Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
SAN FRANCISCO—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the ...
Long-term alliances in pharma enable strategic resource planning and infrastructure development, supporting diverse therapeutic pipelines and ensuring operational reliability. Integrated research, ...
The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future. You may think that Big ...
Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results